Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. - Wikidata - wikimedia - TriplyDB

Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study.

Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study.

http://www.wikidata.org/entity/Q34994293

about

Mitochondrial lipids in neurodegeneration Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users Evaluation of the photooxidation of galactosyl- and lactosylceramide by electrospray ionization mass spectrometry.Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.Integrated molecular landscape of Parkinson's disease Changes in the metabolism of sphingolipids after subarachnoid hemorrhage.Major Alterations of Phosphatidylcholine and Lysophosphotidylcholine Lipids in the Substantia Nigra Using an Early Stage Model of Parkinson's Disease.The Effects of Long-Term Saturated Fat Enriched Diets on the Brain Lipidome.Lipid profiling of parkin-mutant human skin fibroblasts.Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis Ceramides And Stress Signalling Intersect With Autophagic Defects In Neurodegenerative Drosophila blue cheese (bchs) Mutants.Demographic and clinical variables affecting mid- to late-life trajectories of plasma ceramide and dihydroceramide species Plasma sphingolipid changes with autopsy-confirmed Lewy Body or Alzheimer's pathology Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab.Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy.Lipidomics of Alzheimer's disease.Genetic convergence of Parkinson's disease and lysosomal storage disorders.The influence of vascular risk factors on cognitive function in early Parkinson's disease.Ceramide and Its Related Neurochemical Networks as Targets for Some Brain Disorder Therapies.Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment.Instrumented functional reach test differentiates individuals at high risk for Parkinson's disease from controls Plasma sphingolipids and depressive symptoms in coronary artery disease.High Performance Liquid Chromatography-Mass Spectrometry (LC-MS) Based Quantitative Lipidomics Study of Ganglioside-NANA-3 Plasma to Establish Its Association with Parkinson's Disease Patients.Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents.Lipidomic analysis of p-chlorophenylalanine-treated mice using continuous-flow two-dimensional liquid chromatography/quadrupole time-of-flight mass spectrometry.A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise.Clozapine Modulates Glucosylceramide, Clears Aggregated Proteins, and Enhances ATG8/LC3 in Caenorhabditis elegans.Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease.Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health.Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease Evaluation of serum sphingolipids and the influence of genetic risk factors in age-related macular degeneration

P2860

Q28397548-99B7A46A-2102-47E8-9E77-4C9047D70ACD Q28552355-F96B7047-D5A3-4613-A77B-C53506113154 Q30857220-4B5A61D1-EDC4-4C0A-9CE8-71893DCFAF23 Q31097119-4395D20F-89CB-425C-ACCA-43BB72FDA1A3 Q33767544-0AD83B76-1CAE-49F7-9D88-AF111EF45446 Q35175609-3E738129-6FEB-4BB2-986A-000D8F87342F Q36088639-E61CE137-962E-415F-A1C7-AF38C034D4E4 Q36209750-7485FBEF-E753-4E4A-B7EA-913A37A0AECC Q36256274-1F382032-D66B-47B2-8FB6-FDF283EA6124 Q36284241-E2A868FC-99FF-42D2-A82A-743EAA86A23E Q36350326-CCA8AE33-1EF4-42D5-ADFB-3BE684BA8339 Q36409995-4A5F9A2E-F8CE-4688-BF4D-DC52E1B94BB7 Q36855949-71682F27-542A-4907-86C7-CE6709D2EBAF Q37389500-3772A82D-46CE-4F73-9D60-1EEF3A6FBBDE Q37596791-C5AC4E5A-7CB2-42CB-B2F0-A586952AE383 Q38191024-96D177D3-D944-4ED7-B42D-2D9C9683E537 Q38237560-16D02DA4-753C-46D6-838F-2189F3387E0B Q38376727-8C2A2AED-BE1C-4A18-9525-978F8878DEFD Q38607507-F74B353E-5482-487A-A3ED-024F1DA3CB14 Q38811401-9D45D310-75C6-4766-A55B-B932E614B60F Q41992235-1C632D08-5BF9-44FE-AD63-4676524A8624 Q46248790-0CDEF341-6F3A-485D-B010-F860EABD8EC6 Q46264470-E0083F5B-38E3-4EDF-8009-120B6B2C203E Q46426783-3BED6C1F-4D47-4EFE-BC4D-EE9B85494FB1 Q46694997-BCAD152B-F56C-4F7F-8FCB-FC66D3B37982 Q47146081-BE187D95-C78A-4521-9FEB-C72FE10FFD54 Q50481966-51E69CE6-5C92-41A9-8870-D48C161E026B Q51761574-2F8A4976-140C-4172-9F30-2FAB1F3A7D99 Q55451028-60D0600D-7273-4799-B8DE-A0C518A824D1 Q58603525-644737DE-1414-41EF-BF79-11EA2E23879A Q58803874-B51669CC-01F3-426F-903E-6E031C82786A

P2860

Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study.

http://www.wikidata.org/entity/Q34994293

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Plasma ceramide and glucosylce ...... ive impairment: a pilot study.

@ast

Plasma ceramide and glucosylce ...... ive impairment: a pilot study.

@en

Plasma ceramide and glucosylce ...... ive impairment: a pilot study.

@nl

type

label

Plasma ceramide and glucosylce ...... ive impairment: a pilot study.

@ast

Plasma ceramide and glucosylce ...... ive impairment: a pilot study.

@en

Plasma ceramide and glucosylce ...... ive impairment: a pilot study.

@nl

prefLabel

Plasma ceramide and glucosylce ...... ive impairment: a pilot study.

@ast

Plasma ceramide and glucosylce ...... ive impairment: a pilot study.

@en

Plasma ceramide and glucosylce ...... ive impairment: a pilot study.

@nl

P1433

Q34994293-49BBF88B-328F-44A5-9C39-2EF4E837989F

P1476

Q34994293-8F33B819-895C-472B-ACF9-FC5D210699E1

P2093

Q34994293-0D2E5389-8B70-4EC6-A644-588E7168D049

Q34994293-1B8A97A6-568D-4C0C-BC1E-627B56CA30E0

Q34994293-43819143-E56A-4451-BB2D-54E31E745B74

Q34994293-7529DD87-0995-472C-B40A-1957AD90EB37

Q34994293-942A7A50-B5DF-4E02-8736-D0F3BCE42AE5

Q34994293-9F9F6CB8-413E-4E06-8586-C253768FB40C

Q34994293-B5B7C08D-74FF-407D-A28B-6004A6D2130C

Q34994293-F330A360-2572-4ACE-8115-500038824605

P2860

Q34994293-01C87819-EBB4-4BA3-8230-7DADB9278D28

Q34994293-120D82B1-E72E-4365-953E-F5B6AF91C47F

Q34994293-1E1BBD7F-0118-485F-A5F3-91B004045139

Q34994293-34E69FDD-AF6C-4427-AF18-C10CF8957A57

Q34994293-38516EE6-44E9-467F-918F-33572A34A4AE

Q34994293-3BD7E496-F7CA-4707-9C66-0EC01463D6FD

Q34994293-53BDB4EA-4C1D-4641-8E8D-F3F1DCE0C3DE

Q34994293-5963322F-972F-4C9B-90AF-7EB9C37B70EB

Q34994293-59931E00-4440-4FAE-BB2F-76F76B3E9C6A

Q34994293-68205080-A559-42E8-A71B-A7A2F244AD4F

P304

Q34994293-0B5BC67C-8F51-4428-85A2-D59B71D1972E

P31

Q34994293-ED162848-0BA4-4B97-B30A-DFB315FDDCEC

P356

Q34994293-F4B0F09A-B1E3-40A2-8EBE-551FAC2C9314

P407

Q34994293-5696BDAB-A4EE-433F-8EB0-204E1F426917

P433

Q34994293-DDA0E15B-48F3-40BE-9642-8790F37BEE45

P478

Q34994293-40A7F0B0-0D48-4A77-A057-3B4940413595

P50

Q34994293-12414D73-B046-4CBA-97CC-49BECA719901

Q34994293-3FB9A8F6-7F7C-4B5F-BCF4-C60C5CA83FFA

Q34994293-5FBC3685-4A6B-4126-A3C0-A598001AD537

Q34994293-617873CD-1965-4D40-92B9-04502D2873F9

P577

Q34994293-09BB2336-C0A9-4EA9-BFA8-33D884726306

P5875

Q34994293-593C455D-ED96-496B-AB74-0175EDD62D0C

P698

Q34994293-8F87204E-6746-465C-B5A3-0EAEA130638E

P921

Q34994293-E1C4A96D-E2AE-484F-B0DD-7B6C776C3585

P932

Q34994293-A6B17DB8-A56F-4F3B-8142-89123A5794D2

P356

JOURNAL.PONE.0073094

P1433

P1476

Plasma ceramide and glucosylce ...... ive impairment: a pilot study.

@en

P2093

Ann-Kathrin Hauser

http://www.w3.org/2001/XMLSchema#string

Christian Deuschle

http://www.w3.org/2001/XMLSchema#string

Erwin Schleicher

http://www.w3.org/2001/XMLSchema#string

Michelle M Mielke

http://www.w3.org/2001/XMLSchema#string

Norman J Haughey

http://www.w3.org/2001/XMLSchema#string

Rodolfo Savica

http://www.w3.org/2001/XMLSchema#string

Susanne Gräber-Sultan

http://www.w3.org/2001/XMLSchema#string

Veera V R Bandaru

http://www.w3.org/2001/XMLSchema#string

P2860

Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease

Gaucher disease: new molecular approaches to diagnosis and treatment

GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology.

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease.

alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins.

The epidemiology of dementia associated with Parkinson disease.

P304

e73094

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0073094

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Inga Liepelt-Scarfone

Walter Maetzler

P577

2013-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256932073

http://www.w3.org/2001/XMLSchema#string

P698

24058461

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3776817

http://www.w3.org/2001/XMLSchema#string